Key Record Dates
| ClinicalTrials.gov Identifier: | NCT03529110 |
|---|---|
| Brief Title: | DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03] |
| First Submitted : | April 13, 2018 |
| First Submitted that Met QC Criteria : | May 7, 2018 |
| First Posted : | May 18, 2018 |
| Results First Submitted : | March 7, 2022 |
| Results First Posted with QC Comments : | April 4, 2022 |
| Results First Submitted that Met QC Criteria : | April 1, 2022 |
| Results First Posted : | April 29, 2022 |
| Last Update Submitted that Met QC Criteria : | April 16, 2024 |
| Last Update Posted : | April 18, 2024 |